trending Market Intelligence /marketintelligence/en/news-insights/trending/l_yQGASw7H0qK-eZEnAepg2 content esgSubNav
In This List

Galmed Pharmaceuticals chairman resigns; CEO named as replacement

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Galmed Pharmaceuticals chairman resigns; CEO named as replacement

Galmed Pharmaceuticals Ltd. said Chairman Chaim Hurwitz resigned on Dec. 25 to pursue other opportunities, effective immediately.

The Tel Aviv, Israel-based company said CEO and board member Allen Baharaff will replace Hurwitz, subject to shareholder approval.

Hurwitz joined the board in 2011 and has been a member of the audit, nominating and tech committees.

Baharaff, who co-founded the company in 2000, was named CEO in 2012 and president in 2015.

Galmed also appointed board member David Sidransky as chair of the nominating committee and lead independent director, a newly created role that serves as a liaison between the chairman and the independent directors.

Galmed develops therapeutics to treat liver diseases.